Beaufort Securities Reaffirms “Speculative Buy” Rating for Motif Bio plc (MTFB)
Beaufort Securities reissued their speculative buy rating on shares of Motif Bio plc (LON:MTFB) in a research note issued to investors on Thursday. They currently have a GBX 110 ($1.45) price target on the stock.
MTFB has been the topic of a number of other research reports. FinnCap reissued a buy rating and issued a GBX 100 ($1.32) target price on shares of Motif Bio plc in a research report on Thursday, August 24th. Northland Securities reissued a buy rating on shares of Motif Bio plc in a research report on Friday, September 29th. Finally, Peel Hunt reissued a buy rating and issued a GBX 106 ($1.39) target price on shares of Motif Bio plc in a research report on Tuesday, October 31st. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of Buy and an average price target of GBX 101.50 ($1.33).
Shares of Motif Bio plc (LON:MTFB) traded up GBX 0.25 ($0.00) during midday trading on Thursday, reaching GBX 34.50 ($0.45). The company’s stock had a trading volume of 1,844,056 shares, compared to its average volume of 1,130,000. Motif Bio plc has a 52 week low of GBX 21.44 ($0.28) and a 52 week high of GBX 51.75 ($0.68).
COPYRIGHT VIOLATION NOTICE: This story was reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.watchlistnews.com/beaufort-securities-reaffirms-speculative-buy-rating-for-motif-bio-plc-mtfb/1713936.html.
Motif Bio plc Company Profile
Motif Bio plc is a clinical-stage biopharmaceutical company. The Company is engaged in development of antibiotics, which are designed for treatment of infections caused by multi-drug resistant bacteria. It operates in the development and commercialization of pharmaceutical formulations segment. The Company is focused on development of its product, Iclaprim, for the treatment of the bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Streptococcus pneumonia (MDRSP).
Receive News & Ratings for Motif Bio plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motif Bio plc and related companies with Analyst Ratings Network's FREE daily email newsletter.